title: International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.
abstract: In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.
authors.affiliation: Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA. nlin@partners.org
authors.forename: Nancy U
authors.initials: NU
authors.lastname: Lin
authors.forename: Christoph
authors.initials: C
authors.lastname: Thomssen
authors.forename: Fatima
authors.initials: F
authors.lastname: Cardoso
authors.forename: David
authors.initials: D
authors.lastname: Cameron
authors.forename: Tanja
authors.initials: T
authors.lastname: Cufer
authors.forename: Lesley
authors.initials: L
authors.lastname: Fallowfield
authors.forename: Prudence A
authors.initials: PA
authors.lastname: Francis
authors.forename: Stella
authors.initials: S
authors.lastname: Kyriakides
authors.forename: Olivia
authors.initials: O
authors.lastname: Pagani
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Senkus
authors.forename: Alberto
authors.initials: A
authors.lastname: Costa
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008327:Mammography; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011159:Population Surveillance
chemical_list: D014408:Biomarkers, Tumor